Rxivist logo

Multicenter reverse-phase protein array data integration

By Leanne de Koning, Stephan Bernhardt, Kenneth G. Macleod, Bérengère Ouine, Aurélie Cartier, Vonick Sibut, Neil O Carragher, Ulrike Korf, Bryan Serrels, Adam Byron

Posted 31 Aug 2021
bioRxiv DOI: 10.1101/2021.08.31.458377

Among the technologies available for protein biomarker discovery and validation, reverse-phase protein array (RPPA) benefits from unequalled sample throughput. Panels of high-quality antibodies enable the quantification by RPPA of protein abundance and posttranslational modifications in biological specimens with high precision and sensitivity. Incorporation of RPPA technology into clinical and drug development pipelines requires robust assays that generate reproducible results across multiple laboratories. We implemented the first international multicenter pilot study to investigate RPPA workflow variability. We characterized the proteomic responses of a series of breast cancer cells to two cancer drugs. This analysis quantified 86,832 sample spots, representing 108 biological samples, arrayed at three independent RPPA platforms. This unique integrated set of data is publicly available as a resource to the proteomic and cancer research communities to catalyse further analysis and investigation. We anticipate that this dataset will form a reference for the comparison of RPPA workflows and reagents, which can be expanded in the future, and will aid the identification of platform-robust treatment-marker antigens in breast cancer cells.

Download data

  • Downloaded 63 times
  • Download rankings, all-time:
    • Site-wide: 157,926
    • In biochemistry: 4,788
  • Year to date:
    • Site-wide: 120,594
  • Since beginning of last month:
    • Site-wide: 20,764

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide